Search

everythinglearnresearchcommunity

for

Search:↓

The AndroCoV Clinical Scoring is a quick, affordable, and accurate method for diagnosing COVID-19.

Middle-aged and elderly men with BPH had higher hospitalization rates for COVID-19.

As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

Insulin resistance linked to obesity may increase COVID-19 severity.

Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.

Baricitinib helps treat several diseases, including COVID-19, but has side effects and needs careful monitoring.

Higher androgen levels might make COVID-19 worse, especially in men.

5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.

Grey hair and baldness may be linked to COVID-19 severity, but more analysis is needed; post-infectious hair loss is related to the severity of the disease and usually recovers within 3-6 months.

A certain genetic variant in the androgen receptor may predict the severity of COVID-19 in men.

Certain types of rashes in COVID-19 patients may indicate more severe illness and higher risk of death.

The ACE1 gene variant doesn't affect long-COVID symptoms.

Different ACE2 gene versions may affect COVID-19 impact based on age and suggest some hair loss drugs could be potential treatments.

Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.

A man experienced hair loss after getting COVID-19, which improved with treatment and might have been triggered by stress related to the illness.

5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.

Anti-androgen therapy might help protect against COVID-19 infection and reduce death risk.

Hair loss doesn't affect COVID-19 severity.

Tofacitinib may be safe for COVID-19 patients with alopecia without worsening symptoms, based on two cases.

Lifestyle changes during the early COVID-19 outbreak led to more cases of acne and other skin conditions, but fewer cases of rosacea and skin infections.

Women with conditions like PCOS may have a higher risk of COVID-19, but treatments like isotretinoin could help those with acne.

The letter suggests testosterone replacement therapy might worsen COVID-19 outcomes.

Many doctors lack knowledge about COVID-19 skin symptoms and need better education and guidelines.

The Gabrin sign may help identify COVID-19 patients at high risk who also have hair loss due to male hormones.

Tailored neurorehabilitation programs improve life quality for post-COVID-19 patients.

Tocilizumab might be an effective treatment for COVID-19.

Older men with diabetes were more likely to get severe COVID-19 and needed treatments like antivirals for about 2-3 weeks.

Older men with diabetes were more likely to get severe COVID-19 and needed treatments like antivirals for about 2-3 weeks.

People with lower levels of free testosterone tend to have worse COVID-19 outcomes.